Latest Breaking News On - Gage communications - Page 1 : comparemela.com

Medison Pharma; Ipsen: Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Medison Pharma; Ipsen: Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomIntrahepatic cholestasisGastroenterol hepatolGil gurfinkelIoana piscociuDara willisJennifer mooreMedison pharmaWalter perezNicolas boglerAmy wolfIpsen euronextStewart campbellInbal chen

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition

France generalUnited kingdomUnited statesJennifer mooreAmy wolfStewart campbellMedison pharmaBinita kamathDara willisIpsen euronextIntrahepatic cholestasisIoana piscociuNicolas boglerGastroenterol hepatolWalter perezInbal chen

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

France generalUnited kingdomUnited statesStewart campbellInbal chenAmy wolfIpsen euronextNicolas boglerBinita kamathIntrahepatic cholestasisMedison pharmaWalter perezJennifer mooreDara willisGastroenterol hepatolIoana piscociu

Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) Treatment

/PRNewswire/ Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in.

New zealandHong kongUnited kingdomUnited statesDara willisInbal chenMedison pharmaAlbiruni razakPamela mindenHealth canadaGage communicationsPrincess margaret cancer centreEuropean unionDeciphera pharmaceuticalsCorporate communicationsSarcoma life raft group canada

Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma

KIMMTRAK has been approved in Canada and Australia for the treatment of an aggressive form of ocular melanoma and follows approval in the United States and the European Union PETACH TIKVAH, Israel, June 8, 2022 /PRNewswire/ Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is pleased to announce the approval of KIMMTRAK(tebentafusp) by Health Canada and Therapeutics Goods Administration (TGA) for the treatment of unresectable or metastatic uveal melanoma (mUM), a rare and aggressive form of melanoma that affects the eye. KIMMTRAK was developed by Immunocore Holdings plc ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease. The approval will enable Medison to commercia

United statesNew zealandUnited kingdomImmunocore immMarcus butlerDara willisMark moyerVictor papamoniodisMedison pharmaMeir jakobsohnTherapeutics goods administrationTumor immunotherapy programGage communicationsVp international markets at medisonEuropean unionCorporate communications